Rigel Pharmaceuticals (RIGL) Operating Margin (2010 - 2026)
Rigel Pharmaceuticals' quarterly Operating Margin came in at 20.21% in Q1 2026, down 374.0% year-on-year from 7.37% in Q1 2025, and down 39.13% quarter-over-quarter from 33.19% in Q4 2025.
Rigel Pharmaceuticals has reported Operating Margin for 16 years, with the latest figure at 20.21% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 374.0% year-over-year to 20.21%; the trailing twelve-month figure through Mar 2026 stood at 41.56% (up 1993.0% YoY), and the FY2025 full-year result was 42.63%, up 2914.0% from the prior year.
- Operating Margin for Q1 2026 stood at 20.21%, down from 33.19% in the prior quarter.
- The five-year high for Operating Margin was 60.09% in Q2 2025, with the low at 156.92% in Q1 2022.
- Average Operating Margin over 5 years is 8.64%, with a median of 4.05% recorded in 2022.
- Peak annual rise in Operating Margin reached 10900 bps in 2022, while the deepest fall reached 20846 bps in 2022.
- Tracing RIGL's Operating Margin over 5 years: stood at 4.05% in 2022, then soared by 35 bps to 5.49% in 2023, then soared by 426 bps to 28.92% in 2024, then climbed by 15 bps to 33.19% in 2025, then slumped by 39 bps to 20.21% in 2026.
- The last three Operating Margin figures came in at 20.21% (Q1 2026), 33.19% (Q4 2025), and 40.91% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 20.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.21% |
| Dec 31, 2025 | 33.19% |
| Sep 30, 2025 | 40.91% |
| Jun 30, 2025 | 60.09% |
| Mar 31, 2025 | 23.95% |
| Dec 31, 2024 | 28.92% |
| Sep 30, 2024 | 25.41% |
| Jun 30, 2024 | 1.21% |
| Mar 31, 2024 | -23.59% |
| Dec 31, 2023 | 5.49% |
| Sep 30, 2023 | -15.87% |
| Jun 30, 2023 | -19.59% |
| Mar 31, 2023 | -48.81% |
| Dec 31, 2022 | 4.05% |
| Sep 30, 2022 | -82.12% |
| Jun 30, 2022 | -43.48% |
| Mar 31, 2022 | -156.92% |
| Dec 31, 2021 | -104.94% |
| Sep 30, 2021 | -91.84% |
| Jun 30, 2021 | -49.68% |
| Mar 31, 2021 | 51.54% |
| Dec 31, 2020 | -102.04% |
| Sep 30, 2020 | -74.94% |
| Jun 30, 2020 | -108.56% |
| Mar 31, 2020 | 37.71% |
| Dec 31, 2019 | -112.58% |
| Sep 30, 2019 | -57.71% |
| Jun 30, 2019 | -205.04% |
| Mar 31, 2019 | -145.58% |
| Dec 31, 2018 | 6.69% |
| Sep 30, 2018 | -500.92% |
| Jun 30, 2018 | -1,461.16% |
| Dec 31, 2017 | 584.63% |
| Sep 30, 2017 | -1,983.89% |
| Mar 31, 2017 | -452.06% |
| Dec 31, 2016 | -526.23% |
| Sep 30, 2016 | -604.76% |
| Jun 30, 2016 | -158.81% |
| Mar 31, 2016 | -349.31% |
| Dec 31, 2015 | -149.31% |
| Sep 30, 2015 | -52.18% |
| Jun 30, 2015 | -269.56% |
| Mar 31, 2015 | -837.51% |
| Dec 31, 2013 | -294.68% |
| Jun 30, 2013 | -1,634.64% |
| Jun 30, 2012 | -1,658.80% |
| Mar 31, 2012 | -3,108.00% |
| Sep 30, 2011 | -414.26% |
| Jun 30, 2011 | -5,457.47% |
| Sep 30, 2010 | 69.67% |
| Jun 30, 2010 | 54.55% |